Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T21:26:06.837Z.
Calculation as of: 2026-10-06T21:26:06.837Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1c5d1a4dd2ed90e95308857a7b7df8ea0860f9bef9a655807fa9e02aea5f37e0
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Cellectar Biosciences, Inc.
Market Cap
$12.06M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$11.77M
EV/EBITDA Ratio
N/A
TTM Avg
133.45x
3Y Avg
63.52x
5Y Avg
51.85x
Market Cap
$11.55M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$12.58M
EV/EBITDA Ratio
N/A
TTM Avg
26283.45x
3Y Avg
26283.45x
5Y Avg
26283.45x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cellectar Biosciences, Inc. (CLRB) | $12.06M | N/A | N/A | N/A | N/A |
| Lantern Pharma Inc. (LTRN)vs › | $12.17M | N/A | N/A | N/A | N/A |
| Biofrontera Inc. (BFRI)vs › | $11.93M | N/A | N/A | N/A | N/A |
| IRIDEX Corporation (IRIX)vs › | $11.77M | N/A | 133.45x | 63.52x | 51.85x |
| Cytosorbents Corporation (CTSO)vs › | $12.44M | N/A | N/A | N/A | N/A |
| Dare Bioscience, Inc. (DARE)vs › | $12.48M | N/A | N/A | N/A | N/A |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.55M | N/A | N/A | N/A | N/A |
| Tempest Therapeutics, Inc. (TPST)vs › | $12.58M | N/A | 26283.45x | 26283.45x | 26283.45x |
| Caring Brands, Inc. (CABR)vs › | $11.36M | N/A | N/A | N/A | N/A |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $12.78M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
